Atteintes duodéno-pancréatiques de la NEM1 (notice n° 1727017)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03216cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260322002831.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Caillé, Sarah |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Atteintes duodéno-pancréatiques de la NEM1 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 85 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Multiple endocrine neoplasia type 1 (MEN1) is a rare, hereditary, autosomal dominant disease. It is characterized by the presence of cell hyperplasia or tumors of the endocrine system : parathyroid, duodenopancreatic, thymic, and bronchial neuroendocrine tumors (NETs), and pituitary and adrenal adenomas. Duodenopancreatic involvement is common and accounts for 60% of the causes of death in MEN1. Duodenopancreatic NETs can be functional or non-functional, benign or malignant. The most common functional duodenopancreatic NETs are gastrinomas and insulinomas. Patients with MEN1 require multidisciplinary management (gastroenterologist, endocrinologist, pathologist, radiologist, nuclear physician, surgeon) in an expert center and lifelong follow-up. Failure to diagnose MEN1 is a loss of opportunity for the patient and his family. This review is centered on duodenopancreatic NETs in MEN1, specifically diagnostic and therapeutic management. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | La néoplasie endocrinienne multiple de type 1 (NEM1) est une maladie héréditaire rare, de transmission autosomique dominante prédisposant au développement d’une hyperplasie ou de tumeurs neuroendocrines (TNE) dans différents organes. Les atteintes les plus fréquentes, appelées atteintes majeures, sont l’hyperparathyroïdie, les TNE duodéno-pancréatiques, thymiques et bronchiques, ainsi que les adénomes hypophysaires et surrénaliens. Les TNE duodéno-pancréatiques sont fréquentes et représentent 60 % des causes de décès de la NEM1. Elles peuvent être fonctionnelles ou non fonctionnelles, bénignes ou malignes. Les TNE fonctionnelles duodéno-pancréatiques les plus fréquentes sont les gastrinomes et les insulinomes. Les patients atteints de NEM1 nécessitent une prise en charge pluridisciplinaire (gastroentérologue, endocrinologue, anatomopathologiste, radiologue, médecin nucléaire, chirurgien, généticien) en centre expert et un suivi à vie. La méconnaissance du diagnostic de NEM1 est une perte de chances pour le patient et sa famille. Cette revue fait le point sur les TNE duodéno-pancréatiques de la NEM1, notamment la prise en charge diagnostique et thérapeutique. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | gastrinome |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | insulinome |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | NEM1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | tumeurs neuroendocrines |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | gastrinoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | insulinoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MEN1 |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neuroendocrine tumors |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Brixi, Hedia |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Perrier, Marine |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | de Mestier, Louis |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Le Collen, Lauriane |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Deguelte, Sophie |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Delemer, Brigitte |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cadiot, Guillaume |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 29 | 1 | 2022-01-01 | p. 12-23 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2022-1-page-12?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-hepato-gastro-et-oncologie-digestive-2022-1-page-12?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux